Alerta

RESPIRATORY SYNCYTIAL VIRUS VACCINE AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4600256A1

The present disclosure relates to an immunological composition comprising or encoding a human respiratory syncytial virus antigen, and the immunological composition is selected from a nucleic acid immunological composition, a polypeptide immunological composition or a viral immunological composition.

Ultrasound-responsive nanoscale delivery platform for use in the treatment of biofilm-associated diseases

Resumen de: GB2638046A

An ultrasound-responsive nanoscale delivery platform is disclosed for use in treating biofilm-associated diseases. It has been found that the use of a phase-shift nanodroplet/antimicrobial complex platform confers a number of advantages when used in methods for anti-biofllm therapy. Specifically, the inclusion of antimicrobials within the supramolecular structure of the ultrasound-responsive nanoscale delivery platform allows for increased passive cellular and subcellular uptake, stimuli-responsive spatiotemporally controlled drug release, and significantly higher bacterial toxicity in both planktonic cultures and mature biofilms. This platform remains stable in storage at room temperature, in blood components, and does not significantly prematurely release its loaded cargo. The platform may be used as a novel treatment option in biofilm-associated diseases such as, but not limited to, bone and joint infections, cystic fibrosis-associated pleural infections, chronic wounds, and chronic urinary tract infections.

RNA COMPOSITIONS TARGETING CLAUDIN-18.2

Resumen de: AU2023357320A1

The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g., but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g., in combination with a chemotherapeutic agent). The present disclosure further provides RNA backbones containing specific sequences upstream and/or downstream from the coding sequence.

POLYMERIC MICELLE NANOCARRIERS FOR TARGETED EPIDERMAL DELIVERY OF THE HEDGEHOG PATHWAY INHIBITOR TAK-441

Resumen de: CN119997932A

Micellar compositions comprising hedgehog pathway inhibitors and their use in the treatment of skin diseases, skin conditions or skin disorders such as skin cancer, including basal cell cancer, are disclosed.

HYBRID NANOPARTICLES AS MULTIFUNCTIONAL PLATFORM FOR BRAIN TUMOR THERAPY

Resumen de: WO2024075089A1

The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will allow the synergistic effect between drug delivery (also known as chemotherapy) and photothermal therapy. This strategy relies on the construction of hybrid metallic- gold nanoparticles using a dual functionality by lipid nanoparticles (as organic components and drug delivery system) in the core and gold nanorods (as inorganic component and a heat delivery system) in the shell, linked by a tumor-targeting peptide. The active targeting strategy was implemented to guarantee a specific delivery to the brain by using transferrin (targeting the blood-brain barrier) and cRGDfK (not only used to target GB tumor barrier but also as a linker between both inorganic and organic nanoparticles). The invention relates to the field of medicine and biotechnology. The present solution aims at developing targeting hybrid metal-lipid nanoparticle for the treatment of different types of cancer, including glioblastoma, envisioning the establishment of an in vitro/in vivo correlation.

DNA BARREL NANOSTRUCTURE VACCINES

Resumen de: AU2023356193A1

The disclosure relates to nucleic acid-based vaccines for cancer and other diseases.

一种氧化三级胺衍生的两性离子脂质及应用

Resumen de: CN120463627A

本发明属于生物医药技术领域，公开了一种氧化三级胺衍生的两性离子脂质及应用。本发明利用醛、异腈、胺和羧酸的四组分Ugi反应合成可电离阳离子脂质，然后通过对可电离阳离子脂质的三级胺头基进行氧化反应，获得氧化三级胺衍生的两性离子脂质。本发明的氧化三级胺衍生的两性离子脂质可替代辅助磷脂制备脂质纳米颗粒并用于核酸药物递送；能够提升肌肉原位mRNA转染效率并降低肝脏脱靶蛋白表达水平，可满足核酸药物、核酸疫苗以及基因编辑等的应用需求。

一种用于治疗幽门螺杆菌感染并逆转胃肠化生的载纳米胶囊原位凝胶及其应用

Resumen de: CN120459053A

本发明属于生物医药技术领域，公开了一种用于治疗幽门螺杆菌(H.pylori)感染并逆转胃组织肠化生的载纳米胶囊原位凝胶及其应用，具体公开了一种载纳米胶囊原位凝胶，包括纳米胶囊和pH响应性凝胶，所述纳米胶囊分散在凝胶中，包括活性药物、用于包覆所述活性药物的高分子物质和结构稳定剂。本发明提供一种载纳米胶囊原位凝胶，该凝胶通过响应H.pylori感染部位的pH值变化单侧定向释放所载纳米胶囊，纳米胶囊响应H.pylori分泌的脂酶精确释放活性药物，高效杀菌并减缓感染所致损伤。同时，该凝胶还能有效地逆转由H.pylori感染引发的胃肠上皮化生，进一步降低胃癌发生风险，为胃癌预防提供了新思路。

用于细胞内递送多核苷酸的聚合物

Resumen de: WO2024091183A1

The present invention provides an ionizable polymer comprising a constitutional unit according to formula (I). wherein R1 and R2 are as defined in the specification. The ionizable polymer of the invention finds use in the intracellular delivery of polynucleotides in vitro and in vivo. The present invention also provides compositions comprising the ionizable polymer of the invention and a polynucleotide. The compositions disclosed herein find utility as medicaments, in particular as medicaments for the prevention or treatment of an infectious disease, a cancer, or a protein-deficiency disease.

一种抗肿瘤复合纳米疫苗及其制备方法和用途

Resumen de: CN120459283A

本发明属于生物医药技术领域，公开了一种抗肿瘤复合纳米疫苗，包括树突状细胞来源外泌体、肿瘤细胞膜，所述树突状细胞来源外泌体通过融合肿瘤细胞膜携带目标病原体抗原，实现更有效的抗原递送和免疫激活，安全性高，在预防和治疗神经胶质母细胞瘤等恶性肿瘤方面具有一定应用前景。

包含聚肌氨酸脂质偶联物的颗粒组合物

Resumen de: US2024180844A1

The present disclosure features particle compositions, such as liposomes and lipid nanoparticles, comprising a polysarcosine-lipid conjugate, as well as methods of making and using the same.

一种cGAS-STING激活型微针系统及其制备方法与应用

Resumen de: CN120459008A

本发明公开了一种cGAS‑STING激活型微针系统及其制备方法与应用，所述cGAS‑STING激活型微针系统包括相连的针尖和背衬，所述针尖上负载有介孔光敏纳米复合药物，所述介孔光敏纳米复合药物以空心普鲁士蓝纳米颗粒为载体，内部负载小分子药物，外层包覆天然CD44配体多糖；所述小分子药物为羟基脲和毒胡萝卜素的混合物。本发明所述介孔光敏纳米复合药物能够通过温和光热诱导免疫原性细胞死亡，释放损伤相关分子模式；同时激活cGAS‑STING信号通路，促进I型干扰素的分泌，诱导树突状细胞活化并成熟，从而增强T细胞介导的抗肿瘤免疫应答。本发明提供了一种创新的肿瘤免疫治疗策略，具有重要的临床应用价值。

一种单核细胞搭载型产氧脂质体及其制备方法和应用

Resumen de: CN120459057A

本发明涉及一种单核细胞搭载型产氧脂质体及其制备方法和应用，其中制备方法包括：通过固相多肽合成法合成末端为半胱氨酸的脂肽CP和含硫缩酮结构域的脂质RL，提取类囊体膜TK，将脂质成分和脂肽CP使用有机溶剂溶解并混合均匀，将脂质RL和STING激动剂DA使用有机溶剂溶解并混合均匀，去除混合溶液中的有机溶剂；向脂质膜中加入水相溶液进行水合，形成粗脂质体悬浮液，使用超声‑挤出法将类囊体膜TK融合到脂质体上，得到脂质体产品。与现有技术相比，本发明制备的脂质体可以将DA高效递送至胰腺癌深部，激活多种细胞STING通路及免疫应答，缓解乏氧，改善乏氧导致的免疫抑制，从而增强DA的免疫治疗效果。

一种纳米综合体及其制备方法和应用

Resumen de: CN120459319A

本发明涉及肿瘤治疗技术领域，尤其涉及一种纳米综合体及其制备方法和应用。本发明提供的纳米综合体包括中空介孔二氧化硅、掺杂在所述中空介孔二氧化硅壳体骨架中的碳氟链、装载在所述中空介孔二氧化硅空腔内的CaO2、以及通过生物膜仿生涂层修饰在所述中空介孔二氧化硅表面的CD105靶向配体。进一步的，所述中空介孔二氧化硅的空腔内还可以包括Toll样受体7/8双激动剂。本发明提供的纳米综合体不但能够有效缓解肿瘤乏氧和酸性微环境，还能够通过免疫调节增强抗肿瘤免疫反应，提高肿瘤治疗效果。而且，能够精准靶向肿瘤组织，提高药物在肿瘤部位的积累，减少对正常组织的副作用。

一种S-SNACs@TPZ@Cas-A纳米颗粒及其制备方法和在协同抗肿瘤中的应用

Resumen de: CN120459330A

本发明属于生物医药领域，涉及一种S‑SNACs@TPZ@Cas‑A纳米颗粒及其制备方法和在协同抗肿瘤中的应用。本发明构建了S‑SNACs@TPZ@Cas‑A级联响应纳米平台，实现基因编辑与低氧靶向治疗的协同抗肿瘤策略。S‑SNACs@TPZ@Cas‑A在GSH和NTR作用下精准释放Cas9‑RNP和TPZ，成功敲除AMFR，抑制FAM134B泛素化，阻断内质网自噬，并显著削弱肿瘤细胞的增殖、迁移能力，增强氧化应激水平。体内实验显示，该纳米系统有效抑制肿瘤生长、减少肺转移，并通过增强CD8+T细胞和树突状细胞浸润，改善免疫微环境，同时表现出良好的生物安全性。

组合物

Resumen de: WO2024133635A1

A composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionisable lipid capable of forming a lipid nanoparticle; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol-conjugated lipid, wherein the polyethylene glycol (PEG) moiety of the PEG-conjugated lipid has at least 5 consecutive ethylene glycol repeating units, is provided.

含有聚(有机磷腈)聚合物的预防或治疗炎症性疾病的组合物

Resumen de: KR20230169867A

The present invention relates to a drug-loaded thermosensitive poly(organophosphazene) polymer and a pharmaceutical composition for preventing or treating inflammatory diseases comprising the same. An injectable polymer nanoparticle hydrogel system comprising the hydrogel has a long-term anti-inflammatory effect and a sustained release effect of a drug at a therapeutically effective concentration, thereby being used for preventing and treating various inflammatory diseases such as osteoarthritis.

适用于疗法的，特别是抗癌疗法的磁性聚合物纳米胶囊

Resumen de: WO2024033546A1

Magnetic polymer nanocapsules and their use in anti-cancer therapy have been disclosed, which are core-shell polymer nanocapsules carrying hydrophobic active substances, containing magnetic iron oxide nanoparticles.

M2型巨噬细胞膜包裹的FeMn双原子纳米酶的制备方法及应用

Resumen de: CN120459055A

本发明属于纳米酶制备和生物应用领域，具体涉及M2型巨噬细胞膜包裹的FeMn双原子纳米酶的制备方法及应用。通过静电纺丝技术，以氮掺杂碳(BANT)为载体，负载Fe和Mn双原子，合成新型的纳米材料FeMnDA/BCNT双原子纳米酶，然后从天然巨噬细胞中提取巨噬细胞膜，并将其包裹在FeMnDA/BCNT纳米材料上，最终形成M2型巨噬细胞膜包裹的纳米颗粒，即MMFeMnDA/BCNT。本申请制备的MMFeMnDA/BCNT纳米酶具有良好的生物安全性和模拟SOD和CAT酶活性，通过清除H2O2诱导的软骨细胞中过量的ROS，降低炎症因子的表达，从而抑制氧化应激对软骨细胞的损伤。MMFeMnDA/BCNT纳米酶尚未被用于OA的治疗，本发明不仅为双原子纳米酶的进一步应用和扩展提供了科学依据，也为未来治疗骨关节炎和氧化应激相关慢性疾病提供了有效策略和新思路。

一种合成外泌体及其制备方法和应用

Resumen de: CN120459054A

本申请提出一种合成外泌体及其制备方法和应用，将干的细胞膜与包含活性物质和miRNA的缓冲液混合，超声混均；经高压均质、挤出后得到所述合成外泌体；以细胞膜为原材料相比于磷脂和胆固醇的组合，得到的外泌体的稳定性更高；而使用干的细胞膜，相比于湿膜，形成的外泌体具有更好的包载性能。

一种治疗风湿性关节炎的中药透皮贴的制备方法

Resumen de: CN120459182A

一种治疗风湿性关节炎的中药透皮贴的制备方法，可有效解决制备新的中药透皮贴，确保长效、稳定，效果好，治疗风湿性关节炎的用药问题，该中药透皮贴是由中药复方、基质和促渗剂制成，中药复方和基质是由独活、防风、秦艽、川芎、当归、透骨草、赤芍、羌活、水性凝胶和甘油；所述的促渗剂为薄荷醇、冰片、人工麝香和余量为去离子水组成，先萃取原料药，然后制备纳米粒子，再制备第一混合物，再制备第二混合物，调节pH值，涂布，即得治疗风湿性关节炎的中药透皮贴。组分科学合理，贴用方便效果好，长效、稳定的释放药物有效成分，靶向性强，持续缓解风湿性关节炎症状，确保疗效，是治疗风湿性关节炎药物上的一大创新，经济和社会效益显著。

一种含异鼠李素和CRISPR Cas9质粒的递送制剂及其制备方法和应用

Resumen de: CN120459052A

本发明涉及医药技术领域，特别是涉及一种含异鼠李素和CRISPR Cas9质粒的递送制剂及其制备方法和应用。本发明使用聚乳酸‑羟基乙酸共聚物作为递送制剂的内壳材料，包裹疏水性药物异鼠李素，将脂溶性药物异鼠李素制成了亲水性制剂，解决了异鼠李素成药难的问题；通过使用聚乙烯亚胺作为递送制剂的中间层材料，负载CRISPR Cas9质粒，实现基因高效负载，并特异敲除ACSL4基因，抑制铁死亡；通过使用2,3‑二甲基马来酸酐官能化多聚‑L‑赖氨酸作为递送制剂的中间层材料，引入了电荷反转特性；通过使用乏氧视网膜前体细胞膜作为递送制剂的外壳材料，具有良好的生物相容性以及视网膜靶向作用。

吉非罗齐-胡椒碱纳米结构脂质载体及其制备方法和应用

Resumen de: CN120459056A

本发明公开了吉非罗齐‑胡椒碱纳米结构脂质载体及其制备方法和应用，属于医药技术领域。本发明公开的吉非罗齐‑胡椒碱纳米结构脂质载体及其制备方法和应用，首次将吉非罗齐和胡椒碱包载于纳米结构脂质载体中，在改善难溶性药物溶解度的同时，增强了吉非罗齐的降脂效果，减少其不良反应的发生；同时控制制备工艺以实现药物的缓释效果，减少给药次数，提高患者的顺应性，为降脂药物制剂的开发及临床应用提供参考。

一种用于瘤内递送的组合物、抗肿瘤疫苗及其应用

Resumen de: CN120459051A

本发明提供一种用于瘤内递送的组合物、抗肿瘤疫苗及其应用，本发明瘤内递送载体可以实现原位递送表达，并同时包裹mRNA、circRNA、siRNA及小分子化合物等药物，实现多种药物同时递送。本方法制备的多细胞因子z治疗性药物可实现体内外T细胞活化，瘤内注射具有显著的抗肿瘤效果。本方法制备的小核酸药物可实现体内外目的基因敲降，瘤内注射后显著降低肿瘤细胞目的基因表达水平。本方法制备的瘤内递送化合物的脂质纳米颗粒可实现体内外多种肿瘤细胞杀伤，瘤内注射后具有显著的抗肿瘤效果，具有良好的前景和实用价值，为瘤内治疗药物在肿瘤治疗领域中的开发提供了新思路。

一种草本助眠凝胶及其制备工艺

Nº publicación: CN120459187A 12/08/2025

Solicitante:

汉医谷（海南）健康科技集团有限公司

Resumen de: CN120459187A

本发明属于助眠凝胶技术领域，公开了一种草本助眠凝胶及其制备工艺，凝胶由以下成分组成：去离子水，丙二醇，甘油，卡波姆980，三乙醇胺；薰衣草精油1.8%，洋甘菊提取物，苦橙花精油，γ‑氨基丁酸，褪黑素，酸枣仁提取物，乌灵参提取物，磷脂壁材；氯化钠，月桂氮酮；樟脑，冰片；EDTA二钠，苯氧乙醇+乙基己基甘油。本发明适用于长期失眠、入睡困难、失眠多梦、浅睡易醒、焦躁抑郁等睡眠障碍人群；通过纳米微囊技术高透皮吸收率，结合胶体双电层结构产生类电容微电流，协同薰衣草‑洋甘菊‑苦橙花等草本精华与GABA、褪黑素活性成分，多通路调节睡眠中枢，是安全替代安眠药的物理助眠新方案。